Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Director to Leave Position (As CEO of MaRS)

[TechMoose]

Call me an eternal optimist, but I am wondering if Yung Wu's upcoming departure may open up a window for Antibe to step out more and drive visibility.  He's a proven operator.  Smart, high energy and has a demonstrated track record.  Previously as an entrepreneur he sold his company to Oracle and made a lot of money.  

He currently sits on the ATE board and is a major shareholder of ATE.  No doubt he's seriously frustrated by the share price and has been asking questions.  He's driven and I am sure has wanted to see more progress and a move to NASDAQ.  

Press release on his departure is here.  Succession process for such a specialized role as this is a 1 year search process so they have to do this well in advance.   
https://www.marsdd.com/media-centre/mars-discovery-district-ceo-yung-wu-extending-his-five-year-service-commitment-an-extra-year/

Having Yung Wu step up into a more hands on role would be a VERY good thing for ATE.  Just sayin'
Dan and the management team should be paying close attention to this...

[Harper75]

Agree with you on both point.  Probably a little too optimistic that his departure signals increased Antibe focus but with his credentials, we are fortunate to have any of his time.  Big Plus if your optimism rings true....

[MrMugsy]

Ya - as a serial entrepreneur, Yung Wu likely isn't the guy to run ATE. Right now we have a Lawyer and in the future it will likely have a Drug guy - or - sold and someone else will decide how it gets folded in. Right now - I'd be surprised if ATE would make any changes midstream. All eyes on PK/PD ... then P2-Acute ... then readout.  During that time, they are likely planning AME